A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ceritinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.